Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Date:3/31/2011

ipal investigator in the study, commented, "There is a real need for novel therapies in PBC.  The clinically meaningful results from this study are highly supportive of OCA's potential as an effective new drug. We know now that OCA is effective given both in addition to UDCA and, from this study, when given alone.  The reductions in AP levels were very substantial and occurred within a month.  The effects on IgM and inflammatory markers suggest that OCA may have disease modifying properties."

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "This study involved 20 centers in 7 countries and has given us and the PBC thought leaders involved a better understanding of the potent mechanism of action of OCA.  With the international PBC network we have established, we are well positioned to conduct a Phase III program.  We are currently discussing requirements for approval with FDA and have received guidance from the EMA supportive of our proposed program."

Mark Pruzanski, MD, Intercept's Chief Executive Officer, added, "The remarkable results achieved with OCA treatment in this study, together with the previously announced positive Phase II results with our drug added to UDCA in refractory PBC patients and in diabetic patients with nonalcoholic fatty liver disease, supports OCA's potential as a novel hepatoprotective drug that may help preserve liver function in patients with a variety of chronic liver diseases."

About Obeticholic Acid (OCA or INT-747)

OCA is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist. Intercept has announced positive Phase II results from randomized clinical trials in patients with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, and in type 2 diabetics with nonalcoholic fatty liver disease.  These clinical data and OCA's mechanism
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
2. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
3. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
6. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
7. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
8. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
11. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 PharmaPoint: Type 1 Diabetes - ... Type 1 diabetes (T1D) is an autoimmune disease that ... that the body can no longer produce insulin. Over the ... at present, no other treatment can be offered to a ... insulin analogs with different times of action - long-acting as ...
(Date:5/27/2015)...  Precision Advisors ( www.precisionadvisors.com ), a Precision for ... Trends Study of 145 managed care executives. The study ... of big data and predictive analytics, but are not ... Health Information Technology for Economic and Clinical Health Act ... of electronic medical records (EMRs) by 2014. While a ...
(Date:5/27/2015)... May 27, 2015  LumiThera Inc., a developmental ... (PBM) treatment for ocular disorders and disease, announced ... Washington State Life Sciences Discovery Fund (LSDF) ... of the LSDF matching grants worth $500,000 to ... subjects with dry age-related macular degeneration (AMD). ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
... New Somatropin Formulation Demonstrate Advantages ... Over Existing Once-Daily ... Nottingham, UK-based speciality pharmaceuticals,company, today announced that the successful ... the synthetic human growth,hormone (hGH) somatropin. Trials demonstrated therapeutic ...
... released by The Philadelphia AIDS Consortium:, WHO: ... its network of eleven (11) community-based organization,sites located ... 30 AmeriCorps ACTS members working throughout New,Jersey, Delaware ... 9 a.m. until Noon; Media Focused,Event 10:30 - ...
Cached Medicine Technology:Critical Pharmaceuticals Enter Sustained Release hGH Arena 2Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures 2
(Date:5/27/2015)... Beverly Hills, CA (PRWEB) May 27, 2015 ... state of the art web portal focussed on keratoconus ... disease. This relentless progressive disease has its onset in the ... quieting down. The cornea or the front clear part of ... withstand the pressure in the eye. It results in poor ...
(Date:5/27/2015)... Arizona (PRWEB) May 27, 2015 Continuing ... mission of healthier patients in the community, SmartPractice® ... Center (formerly John C. Lincoln). SmartPractice Vice President of ... Michelle Shaw presented a $25,000 check to Paulla Miller, ... HonorHealth’s Breast Health & Research Center on April 30. ...
(Date:5/27/2015)... May 27, 2015 Dr. Omar Ibrahimi, ... in Stamford, CT has been selected as part of ... physicians nationwide (and the only physician in Connecticut) to ... allows for the removal of submental fat (double chin). ... recovery time, no surgery and minimal risks. Dr. Ibrahimi ...
(Date:5/27/2015)... CURE® Magazine and the Bladder ... advance research, provide information and support, and raise awareness ... fifth most common type of cancer, which begins when ... out of control. , “CURE Magazine provides guidance ... the cancer experience through digital and print publications, live ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3
... The number of heat-related deaths is underestimated and underreported ... study published in Biomedical Market Newsletter//(R). ,A ... of heat-related deaths is actually 54% higher than previously ... hyperthermia as a contributing cause of death increased by ...
... estimate of the repercussions of a potential flu pandemic showed ... the underprivileged nations, could pay// with their life. , ... infamous 1918 Spanish flu, which wiped out nearly 20 million ... of Public Health and the University of Queensland studied the ...
... pain are effective, a new review of studies has ... such as// depression and health-related quality of life, they ... ,“Because this analysis was both more inclusive and more ... to date that these interventions are helpful,” said psychologist ...
... eight year old cancer patient may be forced to undertake ... the painful radiotherapy. Having beaten the condition called Wilm’s Tumour ... been confronted by the tumour after a three year respite. ... attack has left the child with a poor quality of ...
... Journal of Neurology Neurosurgery and Psychiatry published a study which ... for treating wrinkled skin could ease writer’s cramp as well. ... hand, arms or fingers which causes pain. This can also ... with their other hand, but in one in four cases, ...
... recently published a study which proves that fish oil supplements ... ,The trial was done on 98 women who ... from 20th week of their pregnancy till the birth of ... not routinely eat more than two weekly portions of fish ...
Cached Medicine News:Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 3Health News:Fish Oil Improves Toddler’s Hand-eye Coordinatio 2
Midstream Catch Kits...
... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
Medicine Products: